AR038002A1 - Antagonistas del receptor de neuroquinina-1, composiciones farmaceuticas y el uso de dichos antagonistas para la preparacion de un medicamento - Google Patents

Antagonistas del receptor de neuroquinina-1, composiciones farmaceuticas y el uso de dichos antagonistas para la preparacion de un medicamento

Info

Publication number
AR038002A1
AR038002A1 ARP020104337A ARP020104337A AR038002A1 AR 038002 A1 AR038002 A1 AR 038002A1 AR P020104337 A ARP020104337 A AR P020104337A AR P020104337 A ARP020104337 A AR P020104337A AR 038002 A1 AR038002 A1 AR 038002A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
independently selected
cycloalkyl
atom
Prior art date
Application number
ARP020104337A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR038002A1 publication Critical patent/AR038002A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)

Abstract

Antagonistas del receptor de la neuroqinina-1 que comprenden un compuesto que tiene la fórmula (1) o una sal farmacéuticamente aceptable del mismo, donde Ar1 y Ar2 están cada uno independientemente seleccionado del grupo que consiste en R17-heteroarilo- y como se muestra en estructura (2); X1 es -O-, -S-, -SO-, SO2, -NR18a, -N(COR12)- o -N(SO2R15)-; X2 es C, S, o SO; cuando X2 es C, entonces Y es O, S, o NR11, cuando X2 es S o SO, entonces Y es O, cuando X1 es -SO-, -SO2-, -N(COR12)- o -N(SO2R15)-, entonces; R1 y R2 están cada uno independientemente seleccionados del grupo que consiste en H, alquilo C1-6, hidroxi(alquilo C1-3), -cicloalquilo C3-8, -cicloalquilalquilo C4-8, -CH2F, -CHF2 y -CF3; o R1 y R2, uno con el otro conjuntamente, y el átomo de C al cual están ambos unidos, forman un anillo alquileno C3-6; cuando X1 es -O-, -S- o NR18a, entonces R1 y R2, están cada uno independientemente seleccionados del grupo que consiste en H, -alquilo C1-6, hidroxi(alquilo C1-3), -cicloalquiloC3-8, -cicloalquilalquilo C4-8, -CH2F, -CHF2 u -CF3, o R1 y R2, conjuntamente uno con el otro y con el átomo de C al cual están ambos unidos forman un anillo alquileno C3-6; o R1 y R2 conjuntamente uno con el otro y con el átomo de C al cual están ambos unidos forman un grupo C=O; R3 está seleccionado del grupo que consiste en H, -alquilo C1-6, hidroxi-(alquiloC1-3); -cicloalquilo C3-8, -CH2F, -CHF2 y -CF3; cada R6 está independientemente seleccionado del grupo que consiste en H, alquilo C1-6, -OR13 y -SR18; cada R7 está independientemente seleccionado del grupo que consiste en H, y alquilo C1-6, o R6 y R7, conjuntamente uno con el otro y con el átomo de C al cual están ambos unidos forman un grupo C=O; n2 es de 1 a 4; R4 y R5 están cada uno independientemente seleccionados del grupo que consiste en -(CR28R29)n1-G y -C(O)(CR28R29)n4-G, donde n1 es de 0 a 5; n4 es de 1 a 5 y G es H, -CF3, -CHF2, -CH2F, -OH, -O-(alquilo C1-6), -SO2R13, -O-(cicloalquilo C3-8), -NR13R14, -SO2NR13R14, -NR13SO2R15, -NR13COR12, -NR12(CONR13R14), -NR12COC(R12)2NR13R14, -CONR13R14, -COOR12, cicloalquilo C3-8(R19)r arilo-, (R19)r heteroarilo-, OC(O)R14, -OC(O)NR13R14, o como se muestra en las estructuras (3) o R4 y R5, conjuntamente uno con el otro y con el átomo de C al cual están ambos unidos forman un grupo C=O o C=NR12, o R4 y R5 conjuntamente uno con el otro y con el átomo de C al cual están ambos unidos forman un anillo de 4 a 7 miembros que contiene de 0 a 3 heteroátomos que están cada uno independientemente seleccionados del grupo que consiste en -O-, -S-, -S(O)-, -SO2-, y -NR18- estando el anillo opcionalmente sustituido con 1 o 2 sustituyentes que están independientemente seleccionados del grupo que consiste en: R30 o R31; o cuando R4 y R5 no forman un anillo, y n2 es 1 o 2, entonces R4 y R6 o R4 y R7 que están carbonos adyacentes, pueden formar un enlace; X3 es -NR20-, -N(CONR13R14)-, -N(CO2R13), -N(SO2R15)-, -N(COR12)-, -N(SO2NHR13), -O-, -S-,-S(O)-, -SO2-, -CH2-, -CF2-, o -CR12F-; R8, R9 y R10 están cada uno independientemente seleccionados del grupo que consiste en H, alquilo C1-6, cicloalquilo C3-8, -OR18, halógeno, -CN, -NO2, -CF3, -CHF2, -CH2F, -CH2CF3, -OCF3, -OCHF2, -OCH2F, -OCH2CF3, -COOR12, -CONR21R22, -NR21COR12, -NR21CO2R15, -NR21CONR21R22, -NR21SO2R15, -NR21R22, -SO2NR21R22, -S(O)n5R15, (R19),arilo- y (R19)r heteroarilo-; R11 es H, -alquilo C1-6, -cicloalquilo C3-8, -cicloalquilalquilo C4-8, -NO2, -CN, o -OR18, R12 es H, -alquilo C1-6, -cicloalquilo C3-6 o -cicloalquilalquilo C4-8; R13 y R14 están cada uno independientemente seleccionados del grupo que consiste en H, alquilo C1-6, cicloalquilo C3-8 o cicloalquilalquilo C4-8, o R13 y R14 conjuntamente uno con el otro forman una cadena alquileno C3 a C6, y con el N al cual están ambos unidos forman un anillo de 4 a 7 miembros que está opcionalmente sustituido con -OR12, donde uno de los átomos de C en la cadena alquileno C3-6 químicamente factible es, opcionalmente , reemplazada con un heteroátomo seleccionado del grupo que consiste en -O-, -S- y -NR18-, R15 es -alquilo C1-6, -cicloalquilo C3-8, cicloalquilalquilo C4-8 o -CF3; R17 es H, -alquilo C1-6, -cicloalquilo C3-8, -cicloalquilo C4-8, -COOR12, -CONR21R22, -NR21R22, -NR21COR12, -NR21CO2R12, -NR21CONR21R22, -NR21SO2R15 o -S(O)n5R15, cada R18 está independientemente seleccionado del grupo que consiste en H, alquilo C1-6, cicloalquilo C3-8, cicloalquilalquilo C4-8 y P(O)(OH)2; cada R18a está independientemente seleccionado del grupo que consiste en H, alquilo C1-6, -cicloalquilo C3-8 y cicloalquilalquilo C4-8, cada R19 está sustituido en el anillo arilo o heteroarilo al cual está unido y está independientemente seleccionado del grupo que consiste en H, -alquilo C1-6, -cicloalquilo C3-8, -cicloalquilalquilo C4-8, -alcoxi C1-6, -OH, -halógeno, -CN, -NO2, -CF3, -CHF2, -OCF3, -OCHF2, -OCH2F, -O-alquilo C1-6, -O-cicloalquiloC3-8, -COOR12, -CONR21R22, -NR21R22, -NR21COR12, -NR21CO2R12, -NR21CONR21R22, -NR21SO2R15 y -S(O)n 5R15; r es de 1 a 3; R20 es H, alquilo C1-6, cicloalquilo C3-8, cicloalquilalquilo C4-8 o -(CH2)n6-heterocicloalquilo; R21 y R22 están cada uno independientemente seleccionados del grupo que consiste en H, -alquilo C1-6, -cicloalquilo C3-8, -cicloalquilalquilo C4-8 y bencilo; o R21 y R22 conjuntamente uno con el otro forman una cadena alquileno C3-6 químicamente factible, y con el N al cual están ambos unidos forman un anillo de 4 a 7 miembros químicamente factible, donde uno de los átomos de C en la cadena alquileno C3-6 químicamente factible está opcionalmente reemplazado con un heteroátomo seleccionado del grupo que consiste en -O-, -S-, o -NR18; R23 y R24 están cada uno independientemente seleccionados del grupo que consiste en H y alquilo C1-6 o R23 y R24, conjuntamente uno con el otro y con el átomo de C al cual están ambos unidos forman un grupo C=O o ciclopropilo; R25 y R26 están cada uno independientemente seleccionados del grupo que consiste en H y alquilo C1-6; o R25 y R26, conjuntamente uno con el otro con el átomo de C, al cual están ambos unidos forman un grupo C=O o ciclopropilo; R27 es H, -alquilo C1-6; R28 y R29 están uno independientemente seleccionados del grupo que consiste en H, -alquilo C1-2, -CH2F, -CHF2 y -CF3; R30 y R31 están cada uno independientemente seleccionados del grupo que consiste en H, -alquilo C1-2, -CH2F, -CHF2 y -CF3; o R30 y R31, conjuntamente uno con el otro y con el átomo de C al cual están ambos unidos forman un grupo C=O o ciclopropilo; n3 es de 1 a 5; n5 es de 0 a 2; y n6 es de 0 a 3; con la condición de que, cuando n5 es 0, y R25 y R26 son cada uno H, entonces X3 es -CH2-, -CF2- o CR12F- o un diaestereómero, enantiómero, estereoisómero, regioestereómero, rotómero, tautómero o prodroga del mismo, composiciones farmacéuticas y el uso de dichos antagonistas para la preparación de un medicamento para tratar emesis, náusea, depresión, ansiedad o tos; una enfermedad respiratoria, una enfermedad inflamatoria, un desorden de la piel, un desorden oftalmológico, fobia y desorden bipolar, dependencia del alcohol, y abuso de sustancias psicoactivas, epilepsia, nocicepción, psicosis, esquizofrenia, enfermedad de Alzheimer, demencia relacionada con Sida, enfermedad de Towne, desorden relacionado con estrés, desorden obsesivo/compulsivo, bulimia, anorexia nerviosa y excesos de comida, manía, síndrome pre-menstrual, desorden gastrointestinal ateroesclorosis, desorden fibrosante, obesidad, diabetes de Tipo II, dolores de cabeza, dolor neuropático, dolor post-operativo y síndromes de dolor crónico, desordenes vesicales y genitourinarios.
ARP020104337A 2001-11-13 2002-11-12 Antagonistas del receptor de neuroquinina-1, composiciones farmaceuticas y el uso de dichos antagonistas para la preparacion de un medicamento AR038002A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33765201P 2001-11-13 2001-11-13

Publications (1)

Publication Number Publication Date
AR038002A1 true AR038002A1 (es) 2004-12-22

Family

ID=23321435

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104337A AR038002A1 (es) 2001-11-13 2002-11-12 Antagonistas del receptor de neuroquinina-1, composiciones farmaceuticas y el uso de dichos antagonistas para la preparacion de un medicamento

Country Status (14)

Country Link
US (1) US7122677B2 (es)
EP (1) EP1451153B1 (es)
JP (2) JP4459621B2 (es)
CN (1) CN100509782C (es)
AR (1) AR038002A1 (es)
AT (1) ATE374183T1 (es)
CA (1) CA2466465A1 (es)
DE (1) DE60222693T2 (es)
ES (1) ES2291538T3 (es)
HK (1) HK1063791A1 (es)
MX (1) MXPA04004477A (es)
PE (1) PE20030592A1 (es)
TW (1) TW200300347A (es)
WO (1) WO2003042173A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
AU2012216435B8 (en) * 2004-07-01 2015-02-19 Opko Health, Inc. Piperidine derivatives as NK1 antagonists
WO2006007540A2 (en) * 2004-07-01 2006-01-19 Schering Corporation Piperidine derivatives as nk1 antagonists
BRPI0619154A2 (pt) * 2005-12-01 2011-09-20 Hoffmann La Roche inibidores do transportador da serotonina (sert)
KR20080108319A (ko) 2006-04-05 2008-12-12 쉐링 코포레이션 약제학적 제형: 8-［｛1-（3,5-비스-（트리플루오로메틸）페닐）-에톡시｝-메틸］-8-페닐-1,7-디아자-스피로［4,5］데칸-2-온의 염 및이를 사용한 치료 방법
AR066191A1 (es) * 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
WO2010028232A1 (en) 2008-09-05 2010-03-11 Schering Corporation Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
MX336071B (es) 2009-08-14 2016-01-06 Opko Health Inc Formulaciones intravenosas de antagonistas de neurocinina 1.
JP5934787B2 (ja) 2011-05-10 2016-06-15 ギリアード サイエンシーズ， インコーポレイテッド イオンチャネルモジュレーターとしての縮合複素環式化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
JP6723930B2 (ja) * 2014-02-07 2020-07-15 エムティーエー タモガトット クタトクソポルトク イロダジャ シグマ−１−受容体アゴニスト化合物の新規使用
CN105367510B (zh) * 2015-11-02 2017-07-21 叶海伟 一种(2R，4S)‑3‑Cbz‑2，4‑二苯基‑1，3‑恶唑烷‑5‑酮的制备方法
CN106967000B (zh) * 2017-04-19 2021-02-02 成都百特万合医药科技有限公司 用于防治肿瘤化疗的医药中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE188472T1 (de) 1992-10-28 2000-01-15 Merck Sharp & Dohme 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
AU682838B2 (en) 1992-12-14 1997-10-23 Merck Sharp & Dohme Limited 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
EP0739336B1 (en) 1994-01-13 1998-08-26 MERCK SHARP & DOHME LTD. Gem-disubstituted azacyclic tachykinin antagonists
US6162805A (en) 1997-04-24 2000-12-19 Merck Sharp & Dohme Limited Use of an NK-1 receptor antagonist and an SSRI for treating obesity
WO2001044200A2 (en) * 1999-12-17 2001-06-21 Schering Corporation Selective neurokinin antagonists

Also Published As

Publication number Publication date
MXPA04004477A (es) 2004-08-11
JP2010090163A (ja) 2010-04-22
HK1063791A1 (en) 2005-01-14
CA2466465A1 (en) 2003-05-22
WO2003042173A8 (en) 2003-10-02
JP2005509031A (ja) 2005-04-07
EP1451153A1 (en) 2004-09-01
CN1585748A (zh) 2005-02-23
ATE374183T1 (de) 2007-10-15
US20030144270A1 (en) 2003-07-31
DE60222693T2 (de) 2008-07-17
CN100509782C (zh) 2009-07-08
ES2291538T3 (es) 2008-03-01
JP4459621B2 (ja) 2010-04-28
TW200300347A (en) 2003-06-01
US7122677B2 (en) 2006-10-17
EP1451153B1 (en) 2007-09-26
WO2003042173A1 (en) 2003-05-22
PE20030592A1 (es) 2003-07-07
DE60222693D1 (de) 2007-11-08

Similar Documents

Publication Publication Date Title
AR038002A1 (es) Antagonistas del receptor de neuroquinina-1, composiciones farmaceuticas y el uso de dichos antagonistas para la preparacion de un medicamento
AR037851A1 (es) Antagonistas de neuroquinina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de medicamentos
RU2405774C2 (ru) Гетероциклические ингибиторы аспартилпротеазы
AR113964A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa
AR071474A1 (es) Derivados de 2-pirrolidinonas activadores de glucoquinasa,composiciones farmaceuticas que los contienen,metodo de preparacion y uso de los mismos para el tratamiento de la diabetes mellitus tipo ii.
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
AR045651A1 (es) Derivados de tiazol como moduladores del receptor de cannabinoide
AR045386A1 (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
RU2016140266A (ru) Спироциклические аминовые производные в качестве модуляторов s1p
AR041672A1 (es) Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo
RU2016146365A (ru) Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b
AR060562A1 (es) Compuestos heterociclicos como antagonistas del receptor il-8. procesos de obtencion y composiciones farmaceuticas.
AR039659A1 (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa
AR068496A1 (es) Piperidinas sustituidas, una composicion farmaceutica que las comprende y su uso para el tratamiento de enfermedades mediadas por la modulacion de la actividad de gpr119.
AR076486A1 (es) Inhibidores de fosfoinositida 3 kinasa y composiciones farmaceuticas que los contienen.
RU2006128589A (ru) Стереоизомерные соединения и способы лечения желудочно-кишечных расстройств и расстройств центральной нервной системы
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
AR056204A1 (es) Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas
PE20060689A1 (es) Derivados de sulfonamidas como antagonistas de receptores orexina 2
AR048939A1 (es) Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios.
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
RU2011146059A (ru) Конденсированное пирролопиридиновое производное
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
AR102989A1 (es) Compuestos antibacterianos con acción sobre topoisomerasas

Legal Events

Date Code Title Description
FB Suspension of granting procedure